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Endogenous antigen presentation
of MHC class II epitopes through
non-autophagic pathways
Carol S. K. Leung*
Department of Haematology, University College London Cancer Institute, University College London, London, UK
Antigenic peptides presented by major histocompatibility complex (MHC) class II
molecules are generally derived from exogenous proteins acquired by antigen presenting
cells. However, in some circumstances, MHC class II molecules can present intracellular
proteins expressed within the antigen-presenting cells. There are several described
pathways by which endogenous antigens are degraded and gain access to MHC class
II molecules. These include autophagy and other non-autophagic pathways; the latter
category includes the MHC class I-like pathways, heat shock protein 90-mediated
pathways, and internalization from the plasma membrane. This review will summarize
and discuss the non-autophagic pathways.
Keywords: antigen presentation, MHC class II molecules, endogenous presentation, intracellular antigens,
non-classical pathways
Introduction
Antigenic peptides presented by major histocompatibility complex (MHC) class II molecules were
thought to bemainly generated from extracellular sources, andMHCclass I peptideswere thought to
be derived from cytosolic and nuclear proteins. In the classical MHC class II presentation pathway,
exogenous antigens are acquired by antigen-presenting cells and delivered into the endo-lysosomal
system, where they are broken down to peptides and presented on MHC class II molecules. While
this holds true, it has become apparent that non-classical pathways also contribute to MHC class
II antigen presentation. Proteins within antigen-presenting cells can endogenously access the MHC
class II pathway and their constituent peptide epitopes can be presented to CD4+ T cells. The first
few studies, shed light on the existence of an endogenous MHC class II pathway, were published in
the 1980s (1–3). Jacobson et al. found that target cells endogenously expressed measles virus matrix
or nucleocapsid proteins were lysed by class II-restricted measles virus-specific CD4+ T cell lines
(4, 5), indicating cytosolic proteins could be endogenously processed and presented in the MHC
class II pathway. Findings from other independent studies also corroborated this by illustrating
that some viral proteins were presented by MHC class II molecules via an endogenous processing
pathway (6, 7). In addition, analysis of purified natural MHC class II ligands has drawn a picture
on the origins of antigens presented by MHC class II molecules. A fraction of the peptides bound
to MHC class II molecules have been found to be derived from intracellular proteins (8–12). In
theory, these intracellular proteins could have been liberated from apoptotic cells and recaptured
as exogenous materials by the antigen-presenting cells. Nevertheless, cytosolic epitopes in these
studies were isolated from cell lines that were not highly phagocytic, and a high rate of cell death
and phagocytosis would be necessary to account for the abundance of some cytosolic epitopes
(13). Therefore, despite exogenous antigens being the main source of antigens in the MHC class
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II pathway, endogenous antigens are able to access the MHC class
II system. In this review, I will highlight the recent findings on
endogenous MHC class II presentation pathways that are not
linked to autophagy.
Hijacking the MHC Class I Machinery
Not long after the discovery of the endogenous MHC class II
presentation of antigens, components of the MHC class I path-
ways, such as proteasome and transporter associatedwith antigen-
processing complex (TAP), were proposed to contribute to the
non-classical presentation of MHC class II epitopes. The protea-
some is a multisubunit enzyme complex that degrades a vari-
ety of proteins into short polypeptides and amino acids in the
cytosol. Its role in endogenous class II presentation has been well
documented (14–17). TAP was first shown to be involved in a
DR1-restricted presentation and processing of a short cytoso-
lic peptide of the influenza hemagglutinin (18), suggesting that
cytosolic peptides could be imported into the endoplasmic retic-
ulum (ER) in a TAP-dependent manner for binding toMHC class
II molecules. However, as invariant chain is associated with the
MHC class II molecules in the ER to prevent premature loading
of peptide, the obstacle has to be overcome in this proposed
pathway. Lechler and Aichinger suggested that stress conditions,
such as viral infection, could alter the ratio of MHC class II
molecules to invariant chain, resulting in the binding of unfolded
or partially unfolded proteins to MHC class II molecules. They
also proposed that high expression levels of antigen could allow
antigen loading in the ER (19, 20). Indeed, it has been shown
recently that unfolded proteins could compete with invariant
chain and bind to MHC class II molecules in the ER before
transporting to the cell surface (21). However, the same study
did not find evidence that the protein–MHC class II complex
on the cell surface could induce CD4+ T cell activation. Inter-
estingly, there are numerous examples of CD4 epitopes being
presented in the absence of invariant chain expression (22–24),
and that invariant chain-negative cancer cells have been used
as a means to stimulate tumor-specific T cells (25). Apart from
loading the epitopes in the ER, the peptides could be loaded
on internalized mature MHC class II molecules through the
recycling pathway. In this pathway, the antigens may require
proteasome degradation and TAP for delivering the epitopes to
the early endosome, where they are loaded onto recycling MHC
class II molecules. In fact, it has been demonstrated that endoge-
nous presentation could be mediated through the recycling of
MHC class II molecules (26, 27). Tewari et al. studied three I-Ed
restricted epitopes of PR8 influenza (28) and found two of these
epitopes were efficiently generated by a proteasome- and TAP-
dependent pathway that involved recycling of the MHC class
II molecules. Others have shown that MHC class II molecules
could internalize and exchange antigenic peptides in the endo-
somes (29, 30), and that the peptide–MHC class II complex could
rapidly recycle back to the plasma membrane through a clathrin-
independent pathway (31). The conformation of the antigen is
crucial for its access to the intracellular processing pathway and
binding to the recycling of MHC class II molecules (32), as
incompletely folded antigen could lead to selective binding to
recycling of MHC class II molecules and result in CD4+ T cell
activation.
Regulation by Heat Shock Protein
90 (HSP90)
Recent studies on the processing of tumor-associated antigens
have uncovered the involvement of components other than the
MHC class I machinery in endogenousMHC class II presentation
pathways. NY-ESO-1 is a cancer testis antigen expressed in a wide
variety of malignant cells and spontaneous immune responses
against this antigen have been detected in cancer patients (33). As
CD4+ T cells could directly recognize MHC class II positive and
NY-ESO-1-expressing tumor cells (34), one would then question
the underlying mechanism of how this intracellular antigen is
processed to CD4+ T cells. Tsuji et al. attempted to solve this by
studying NY-ESO-1 epitope processing in the melanoma cell line
SK-MEL-37 in the presence of various pharmacological inhibitors
(35). The processing of the epitope NY-ESO-195–106, restricted
through DR01, was inhibited by the proteasome inhibitor epox-
omicin but not lactacystin, indicating the processing of this epi-
tope was dependent on the chymotrypsin-like activity of the
proteasome. Also, tripeptidyl peptidase II and TAP were involved
in degrading the protein and peptide transport. The processing
required endosomal protease as treatment with chloroquine and
leupeptin inhibited the presentation. However, macroautophagy
and chaperone-mediated autophagy were not involved. Instead,
the presentation was dependent on endosomal protease and
chaperoning by the cytosolic HSP90. This chaperone protein is
inducible by stress and is required for the functioning of a large
number of client proteins. Both HSP90 inhibitor 17-DMAG and
si-RNA-mediated silencing of the protein inhibited the CD4+
T cell response to epitope NY-ESO-195–106, indicating the par-
ticipation of HSP90 in the presentation. HSP90 has also been
implicated in direct and cross antigen presentation by professional
antigen-presenting cells for CD8+ T cell recognition (36–39);
and its role in chaperoning and transferring antigenic peptides
to MHC class II molecules in professional antigen-presenting
cells has been described (40, 41). However, unlike the other NY-
ESO-1 epitope, the DP04-restricted epitope NY-ESO-1157–170 was
processed independent of HSP90, as treatment with the HSP90
inhibitors, 17-DMAG and redicicol as well as si-RNA-mediated
silencing, had no effect in the presentation (42). This DP04-
restricted presentation required TAP-mediated peptide transport
and endosomal recycling. More studies are required to confirm
the role of HSP90 on endogenous processing of MHC class II
epitopes.
Internalization from the Plasma Membrane
Another tumor antigen, gp100, is a melanosomal antigen that
has been reported to access the endogenous MHC class II path-
way and present efficiently to gp-100-specific CD4+ T cells
(43). The presentation was inhibited by removing the putative
NH2-terminal signal sequence and the last 70 residues in the
COOH terminus in gp100, supporting the important role of
melanosomal and endosomal location for efficient MHC class
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II presentation. In the study by Lepage and Lapointe, gp100
transfectants were used to assess the presentation of the DR07-
restricted epitope gp100170–190. The cell-surface expression of
gp100 correlated with MHC class II presentation, suggesting that
gp100 might transport to the cell surface before internalizing
to relevant endosomal or lysosomal compartments to meet the
MHC class II molecules for presentation. The correlation between
gp100 cell-surface expression and the endogenous presentation
of protein was also confirmed in another study. Robila et al.
analyzed the MHC class II endogenous processing of DR04-
restricted epitope gp10044–59 and demonstrated that endosomal
localization and processing by acidic proteases were necessary
for gp10044–59 presentation (44). The major source of this epi-
tope was from the internalization of the gp100 protein from the
plasma membrane through the AP2 adaptor protein. In these
studies, although the authors claimed gp100 was endogenously
processed in the MHC class II pathway, their experiments could
not exclude the possibility that the antigen might have been
processed via a conventional exogenous route. As gp100 is a
membrane-bound glycoprotein that can be secreted by cells (45),
it is possible that MHC class II presentation in these studies
did not result from processing of endogenous antigen, but was
rather derived from exogenous antigen released from other cells
in the culture. This could be easily clarified by a cell-mixing
experiment, where gp100 expressing MHC-mismatched target
cells are first mixed with MHC-matched target cells lacking the
antigen, then co-cultured with gp100-specific CD4+ T cells. If
CD4+ T cell response could be detected, then gp100 would
be transferred and processed in the conventional manner. In
fact, intercellular antigen transfer plays a role in the process-
ing of MHC class II antigens for CD4+ T cell recognition (46,
47). However, as this pathway involves antigen being secreted
and then recaptured as exogenous material by the antigen-
presenting cells, this is generally considered to be conventional
processing.
Conclusion
This review has summarized the recent studies on endoge-
nous antigen presentation of MHC class II epitopes through
non-autophagic pathways. Although different pathways have been
described in the non-classical MHC class II processing, there are
still questions to be addressed. How are different epitopes selected
for different endogenous presentation pathways to CD4+ T cells?
Why are some epitopes better presented than the others? Despite
having the sameHLA restriction and epitope in a proximal region
within an antigen, antigen-specific T cells display differential
capability to recognize tumor cells. Tsuji et al. has shown that
DR01-restricted CD4+ T cell lines specific for the NY-ESO-
195–106 epitope were able to respond to un-manipulatedmelanoma
cell lines, while CD4+ T cells specific to NY-ESO-187–98 could
not (35). Another study also reported that two epitopes of the
Epstein–Barr virus antigen EBNA1, namely VYG (EBNA1509–528)
and PQC (EBNA1529–548), both restricted through DR11, behaved
differently. Whereas VYG-specific CD4+ T cells could recognize
EBV-positive LCLs directly, it was not the case for the PQCepitope
(48). Poor presentation of the latter might be due to the fact that
PQC is more prone to lysosomal protease degradation. However,
how VYG is endogenously presented in theMHC class II pathway
is still not known. In addition, most of these experiments have
been in vitro studies; the pathways should be validated in vivo.
Gaining a better understanding of these pathways will give insight
in the development of vaccines and immunotherapies.
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